Detalhe da pesquisa
1.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Haematologica
; 109(2): 543-552, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37560813
2.
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Haematologica
; 109(1): 115-128, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199127
3.
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634126
4.
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Ann Hematol
; 103(2): 451-461, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110588
5.
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Blood
; 137(14): 1879-1894, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150388
6.
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica
; 106(12): 3079-3089, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179471
7.
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Ann Hematol
; 100(6): 1497-1508, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33914097
8.
Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Ann Hematol
; 99(3): 675, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002657
9.
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.
Eur J Haematol
; 105(2): 138-147, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32243655
10.
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols.
Eur J Haematol
; 104(3): 162-169, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724208
11.
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Ann Hematol
; 98(11): 2467-2483, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31667544
12.
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.
Eur J Haematol
; 102(1): 79-86, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30267597
13.
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biol Blood Marrow Transplant
; 24(8): 1754-1758, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29649620
14.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Br J Haematol
; 201(6): 1239-1244, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057357
15.
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Ann Hematol
; 97(5): 923, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473097
16.
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Ann Hematol
; 97(5): 763-772, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29392425
17.
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Cancer Immunol Immunother
; 66(2): 233-245, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27530271
18.
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Br J Haematol
; 174(5): 700-10, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27118319
19.
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Cancer Immunol Immunother
; 65(4): 453-63, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26059279
20.
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Br J Haematol
; 169(2): 188-98, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25521006